Waystar makes $1.25B bet on AI for healthcare payments
Posted:
Waystar has signed a definitive agreement to acquire Iodine Software, a $1.25 billion deal that seeks to empower healthcare payments with more AI capabilities.
Doctors will be able to prescribe a new treatment for people with inflammatory bowel disease (IBD), after the UK medicines watchdog approved guselkumab (Tremfya) for use on the NHS.
Read more here.
The breakthrough, made by scientists at the Centre for Neuropsychiatric Genetics and Genomics (CNGG) at Cardiff University, provides new information and improves the understanding and future treatment development for schizophrenia.
Read more here.
Attendees
Sponsors and Exhibitors
Contact us